Equillium acquires bioniz therapeutics significantly expanding pipeline of novel immunomodulatory drug candidates

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired bioniz therapeutics, inc., a privately held clinical-stage biotechnology company. bioniz developed its novel structured-domain peptides, including bnz-1 and bnz-2, entirely in-house from its proprietary product discovery platform. th
EQ Ratings Summary
EQ Quant Ranking